Pricing

Log inSign up

Iovance Biotherapeutics

355 people · 0 jobs
‌

Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.

Industries

Biotechnology

Headquarters

San Carlos, United States

Employees

201-500

Links

Org chart

Frederick G. Vogt
Interim CEO, President & General Counsel
Collapse
IB
Igor Bilinsky
COO
Howard B. Johnson
Chief Business Officer
Brian Shew
SVP, Head of Digital & Information Technology
Tracy Winton
EVP, Human Resources
Kevin Smyth
EVP, Quality
Hequn Yin
SVP, Research
SB
Stefanie Bulilan
Sr. Director Quality Systems And Compliance
KE
Kerry Elizabeth Wilson Esq.
Executive Counsel
Sean Rocca
Executive Counsel
DK
Dan Kirby
Chief Commercial Officer (cco)
Sara Pellegrino
Svp, Investor Relations & Corporate Communications
Kun Wang
Senior Patent Counsel
Jonathan W.
Associate General Counsel
MR
Matthew Rosinack
Senior Vice President Finance
Michele Fernandes
SVP Portfolio Management
RM
Rana Fiaz M.d.
Executive Medical Director
Hana Sahdev
Senior Securities And Corporate Counsel
Jen Saunders
Senior Director, Investor Relations & Corporate Communications

Board & advisors

Iain Dukes
Chairman
Ryan Maynard
Director
Wayne Rothbaum
Director
Michael Weiser
Director
Athena Countouriotis
Director
WY
Wendy L. Yarno
Director

Similar companies

Editas Medicine

5 followers

Arcus Biosciences

3 followers

Gilead Sciences

169 followers

Regeneron

141 followers

Illumina

80 followers

Agilent Technologies

88 followers

Verily Life Sciences

48 followers

Alexion Pharmaceuticals

48 followers

GRAIL

30 followers

Cytiva

19 followers

CRISPR Therapeutics

13 followers

Explore companies